ITMCTR2100004702招募中4 期
A randomized, double-blind, placebo-controlled, multi-center clinical study to evaluate the effectiveness and safety of Xuefu Zhuyu Capsules for angina pectoris after PCI
试验速览
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional study
入排标准
- 年龄范围
- 30 至 75（—）
- 性别
- All
入选标准
- •1. Aged 30-75 years;
- •2. Patients with angina pectoris symptoms within 12 months after PCI;
- •3. Patients with Qi stagnation and blood stasis syndrome based on TCM differentiation;
- •4. The patient signs an informed consent form, has good compliance, and cooperates with follow-up visits and re-examinations.
排除标准
- •1. Diagnosed as STEMI, or diagnosed as NSTEMI who is at high risk by Grace score;
- •2. Patients with congenital heart disease, severe pulmonary hypertension, malignant tumors, severe COPD;
- •3. Valvular disease (LVEF < 30%), with cardiomyopathy, pericardial effusion, severe arrhythmia;
- •4. Before screening, any laboratory test index meets the following criteria: Admission liver and kidney function prompts: ALT, AST > 1.5 times the upper limit of normal value, Cr > 1.2 times the upper limit of normal value (refer to the laboratory test normal value of the research center Scope); Other clinically significant laboratory tests are abnormal and the investigator determines that it is not suitable to be included in the group;
- •5. People with allergies or allergies to the test drug Xuefu Zhuyu Capsules, excipients or similar ingredients;
- •6. Suspected or true history of alcohol or drug abuse;
- •7. Pregnant or breastfeeding women or those who have planned pregnancy in the near future and are unwilling to use contraceptive measures;
- •8. Patients who have participated in other clinical trials within 1 month before enrollment;
- •9. The investigator believes that it is not appropriate to participate in this clinical trial.
研究者
相似试验
进行中（未招募）
1 期
Study on the safety of the drug runcaciguat and how well it works when given at the highest dose as tolerated by the individual patient whose kidneys are not working properly and suffering at the same time from a disease of the heart and the blood vessels and high blood sugarTreatment of cardiovascular and renal disease in patients with chronic kidney diseaseMedDRA version: 21.1Level: PTClassification code 10064848Term: Chronic kidney diseaseSystem Organ Class: 10038359 - Renal and urinary disordersMedDRA version: 20.0Level: PTClassification code 10001580Term: AlbuminuriaSystem Organ Class: 10038359 - Renal and urinary disordersEUCTR2019-003297-53-ESBayer AG432
进行中（未招募）
不适用
A randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety and tolerability of licarbazepine 750-2500 mg/d combined with risperidone in the treatment of manic episodes of bipolar I disorder over 6 weeksBipolar I disorder, manic and mixed episodesEUCTR2004-000113-18-HUovartis Hungaria Kft.430
进行中（未招募）
1 期
Phase 2b dose-ranging study of ALX-0171 in infants and young children hospitalized for RSV lower respiratory tract infectioRSV lower respiratory tract infectionMedDRA version: 20.1Level: PTClassification code 10061603Term: Respiratory syncytial virus infectionSystem Organ Class: 10021881 - Infections and infestationsEUCTR2016-001651-49-SKAblynx NV180
进行中（未招募）
1 期
A randomized, double-blind, placebo-controlled, multicenter phase III study of RAD001 adjuvant therapy in poor risk patients with Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 versus matching placebo after patients have achieved complete response with first-line rituximab-chemotherapyDiffuse Large B-Cell LymphomaMedDRA version: 19.0Level: PTClassification code 10012818Term: Diffuse large B-cell lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2008-000498-40-HUovartis Pharma Services AG487
进行中（未招募）
1 期
Safety and efficacy study in patients with moderate to severe nail psoriasisModerate to severe nail psoriasisMedDRA version: 18.0Level: PTClassification code 10028703Term: Nail psoriasisSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersEUCTR2012-005413-40-BEovartis Pharma Services AG195